NervGen Brings Advanced Imaging to Planned NVG-291 Trials

NervGen Brings Advanced Imaging to Planned NVG-291 Trials

307559

NervGen Brings Advanced Imaging to Planned NVG-291 Trials

A partnership will allow NervGen to use Imeka‘s proprietary biomarker imaging technology to precisely measure changes in the brain and spinal cord in its upcoming clinical trials, including a study of NVG-291 in people with multiple sclerosis (MS) NervGen plans to initiate Phase 1b/2 trials into its lead candidate for neural repair in MS patients, and in people with spinal cord injury, next year. A Phase 1/2a trial is also planned for Alzheimer’s disease. “We are very excited to apply…

You must be logged in to read/download the full post.